The purpose of this study is to learn if a surgical technique called intraoperative
lymphatic mapping can accurately identify the lymph node that is at greatest risk if
endometrial or cervical cancer spreads to the lymph nodes.
Early cervical cancer is usually treated by removing the cervix, tissue around the cervix,
and the upper vagina. If needed, the uterus is also removed. The treatment also includes
removing lymph nodes from the pelvis. Endometrial cancer is usually treated by removing the
cervix, uterus, fallopian tubes and ovaries.
The treatment also includes removing lymph nodes from the pelvis.
Patients with FIGO stage I endometrial cancer or patients with FIGO stage I-IIA invasive
cervical cancer and who will be undergoing surgical management to include a lymphadenectomy.
↓ Injection of radioisotope and preoperative lymphoscintigraphy with Tc99m either the day
before or on the day of surgery by the Nuclear Medicine Department.
↓ Intraoperative lymphatic mapping with blue dye and gamma probe.
↓ Hysterectomy, Radical hysterectomy and/or radical trachelectomy and pelvic
- Patients with endometrial cancer diagnosed on endometrial biopsy or dilatation and
- Patients with invasive cervical cancer diagnosed on cervical biopsy or cone biopsy.
- Patients with a performance status of 0, 1, 2, or 3 by the Gynecologic Oncology Group
- Patients with stage I to ~IIA invasive cervical cancer disease according to the
International Federation of Gynecology and Obstetrics (FIGO) clinical staging
- Patients with clinical stage I endometrial cancer
- Patients who will undergo surgery to include a hysterectomy, radical hysterectomy
and/or radical trachelectomy and bilateral lymphadenectomy via laparotomy or
- Patients who have signed an approved informed consent.
- Patients with history of prior pelvic or para-aortic lymphadenectomy.
- Patients with stage IIB-IV invasive cervical cancer by FIGO criteria.
- Patients with recurrent endometrial or cervical cancer.
- Patients with prior pelvic radiation.
- Any patient with endometrial or cervical cancer treated with neoadjuvant chemotherapy
and radiation therapy.
- Patients with a performance score of 4 by the Gynecologic Oncology Group criteria or
who are not good surgical candidates (Appendix).
- Patients with grossly infected primary tumors.
- Patients with known allergy to triphenyl-ethane compounds.
- Patients with known deficiency of Glucose-G-Phosphate Dehydrogenase.
- Patients with known Hemolytic Anemia from Pyruvate Kinase and G6PD Deficiencies.
- Severe Renal Disease.